吡格列酮抗炎作用对代谢综合征患者胰岛素敏感性、血管内皮细胞功能的影响

目的研究吡格列酮对伴糖耐量减低（1GT）的代谢综合征（MS）患者血管内皮细胞功能的影响。方法对30例伴IGT、的MS患者采用吡格列酮45mg／d治疗8周。在治疗前后分别测定胰岛素敏感度检测指数（QUICKI）、肱动脉内皮依赖性舒张功能（FMD）和硝酸甘油诱导的非内皮依赖性舒张功能（NID），高敏C反应蛋白（hs-CRP）改变。结果治疗后FMD明显改善（P〈0．01），QUICKI指数升高（P〈0．05）；hs-CRP水平降低（P〈0.01）。结论吡格列酮能明显改善IGT的MS患者的血管内皮细胞功能，其机制可能与改善体内胰岛素抵抗，抑制慢性炎症反应有关。

Anti-inflammatory effect of pioglitazone on insulin sensitivity and vascular endothelial cell function of patients with metabolic syndrome

Objective To explore the beneficial effects of pioglitazone on endothelial func- tion in metabolic syndrome （MS） patients with impaired glucose tolerance （IGT）. Methods Thir- ty MS patients with IGT were administrated pioglitazone （45 mg/d） for eight weeks. The quantita- tive insulin sensitivity check index （QUICKI）, endothelium-dependent vasodilation （flow-mediated vasodilation, FMI）） and endothelium-independent vasodilation （nitroglycerin-induced vasodilation, NID） were measured in the brachial artery by high resolution ultrasound technique were measured before and after treatment respectively. The changes of hsCRP were assessed as well. Results After treatment, the levels of FMD, QUICKI and hsCRP were improved significantly （P 〈 0.05, P 〈 0. 01 ）. Conclusion Pioglitazone treatment improves endothelial vasodilator function in MS patients via enhancing insulin sensitivity and inhibition of chronic inflammation.